Don't want ads? Subscribe or login now.

BEAT Rules Could Kill Clinical Trials, Industry Claims

By Alex M. Parker · March 25, 2019, 8:00 PM EDT

U.S. Treasury rules administering the 2017 tax law's base erosion and anti-abuse tax represent an "existential" threat to the business model of companies that administer clinical trials for pharmaceutical firms, two...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Alex

June 11, 2021
Divide On Scope Remains In Global Minimum Tax Pact
June 10, 2021
Annual Asset Taxation Of Wealthy Needs More Time, Official Says
June 09, 2021
Biden Faces Tough Sell On Corp. Alternative Minimum Tax
June 07, 2021
Australia To Finalize Intangibles Tax Guidance
June 04, 2021
Proposed Foreign Tax Rule Raises Blacklist Fears
June 02, 2021
ViacomCBS Avoids $4B In Tax Through Licensing IP, Group Says
May 28, 2021
Stock Option Expensing Puts Corp. Taxes In Public Spotlight
May 27, 2021
Global Minimum Tax May Require New Treaties, Panelists Say
May 26, 2021
Africa Boosting Revenue With Info Exchange, OECD Report Says
May 26, 2021
Ariz. Man Owes $309K In FBAR Penalties, Calif. Court Says

BEAT Rules Could Kill Clinical Trials, Industry Claims

Related Sections

Recent Articles By Alex